[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633188":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":35,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":35,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":35,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":39,"whyStopped":35,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"high dex group","patients will receive 3 mcg\u002Fkg intranasal dexmedetomidine 45minutes before surgery",[12],"Other: high dex group",{"label":14,"type":6,"description":15,"interventionNames":16},"low dex group","patients will receive 2 mcg\u002Fkg intranasal dexmedetomidine 45minutes before surgery",[17],"Other: low dex group",[19,23],{"type":6,"name":9,"description":10,"armGroupLabels":20,"otherNames":21},[9],[22],"group 1",{"type":6,"name":14,"description":15,"armGroupLabels":24,"otherNames":25},[14],[26],"group 2",[28],{"name":29,"affiliation":5,"role":30},"sarah m elgamal, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","01005496440",null,"sarahelgamal1990@yahoo.com",[38],{"facility":5,"status":39,"city":40,"state":35,"zip":35,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Alexandria","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],29.91582,31.20176,{"lat":47,"lon":46},[50],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},{"type":30,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"sarah mohamed","lecturer","100633188","effect-of-intranasal-dexmedetomidine-on-the-incidence-of-emergence-agitation-in-children-undergoing-strabismus-surgery-100633188",false,"NCT07523438","Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery","Effect of Two Different Doses of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery , A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age: 3-6 years, both sexes\n* ASA physical status class I , II.\n\nExclusion Criteria:\n\n* history of neurological and psychiatric disease\n* body mass index \\> 20 kg m-2\n* allergy to dexmedetomidine\n* patients on medical treatment which has any sedative effect\n* mentally retarded children","ALL","3 Years","6 Years",{"count":65,"type":66},120,"ESTIMATED","INTERVENTIONAL",[69],"NA","Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg \u002Fkg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg\u002Fkg",[72,73],"Dexmedetomidine","Emergence Agitation",[72,75,76],"emergence agitation","strabismus surgery","2026-04-05",{"date":79,"type":80},"2026-04-13","ACTUAL",{"date":82,"type":80},"2026-03-01",{"date":84,"type":66},"2026-12-01",{"name":5,"class":6},1]